{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:50:50Z","timestamp":1795211450736,"version":"4.10.3"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.euroneuro.2024.11.008","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T09:02:14Z","timestamp":1733389334000},"page":"69-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2000-7691","authenticated-orcid":false,"given":"Danica E.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Weisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Chisamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5170-0265","authenticated-orcid":false,"given":"Erica S.","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.J.","family":"Chen-Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-6735","authenticated-orcid":false,"given":"J Don","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.euroneuro.2024.11.008_bib0001","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41386-022-01266-9","article-title":"Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial","volume":"47","author":"Abdallah","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.euroneuro.2024.11.008_bib0002","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11634","article-title":"Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression","volume":"79","author":"Albott","year":"2018","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.11.008_bib0003","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2024.11.008_bib0004","series-title":"Evidence Brief: Treatment of Comorbid Conditions","author":"Beech","year":"2021"},{"issue":"6","key":"10.1016\/j.euroneuro.2024.11.008_bib0005","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/jts.22975","article-title":"Minimal important difference metrics and test\u2013retest reliability of the PTSD Checklist for DSM -5 with a primary care sample","volume":"36","author":"Blanchard","year":"2023","journal-title":"J. Traumat. Stress"},{"issue":"6","key":"10.1016\/j.euroneuro.2024.11.008_bib0006","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/jts.22059","article-title":"The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation","volume":"28","author":"Blevins","year":"2015","journal-title":"J. Traumat. Stress"},{"issue":"11","key":"10.1016\/j.euroneuro.2024.11.008_bib0007","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1037\/pas0000254","article-title":"Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders\u2013Fifth Edition (PCL-5) in veterans","volume":"28","author":"Bovin","year":"2016","journal-title":"Psycholog. Assess."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1080\/20008198.2021.2011602","article-title":"The nature of posttraumatic stress disorder in treatment-seeking first responders","volume":"13","author":"Bryant","year":"2022","journal-title":"Eur. J. Psychotraumatol."},{"issue":"6","key":"10.1016\/j.euroneuro.2024.11.008_bib0009","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s11606-006-0101-4","article-title":"Prevalence of depression\u2013PTSD comorbidity: implications for clinical practice guidelines and primary care-based interventions","volume":"22","author":"Campbell","year":"2007","journal-title":"J. Gener. Internal Med."},{"key":"10.1016\/j.euroneuro.2024.11.008_bib0010","series-title":"A Mixed Model Approach for Intent-to-Treat Analysis in Longitudinal Clinical Trials with Missing Values","author":"Chakraborty","year":"2009"},{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.008_bib0011","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/0004867416631828","article-title":"Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation","volume":"51","author":"Cusin","year":"2017","journal-title":"Austr. N. Zeal. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2024.11.008_bib0012","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/life12020196","article-title":"Novel pharmacological approaches to the treatment of depression","volume":"12","author":"Elias","year":"2022","journal-title":"Life"},{"issue":"7","key":"10.1016\/j.euroneuro.2024.11.008_bib0013","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Molecul. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2024.11.008_bib0014","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder","volume":"178","author":"Feder","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2024.11.008_bib0015","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2024.11.008_bib0016","doi-asserted-by":"crossref","first-page":"141","DOI":"10.31887\/DCNS.2015.17.2\/jflory","article-title":"Comorbidity between post-traumatic stress disorder and major depressive disorder: alternative explanations and treatment considerations","volume":"17","author":"Flory","year":"2015","journal-title":"Dialog. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.euroneuro.2024.11.008_bib0017","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s40501-020-00203-1","article-title":"Predicting and managing treatment non-response in posttraumatic stress disorder","volume":"7","author":"Fonzo","year":"2020","journal-title":"Curr. Treatm. Opti. Psychiatry"},{"issue":"15","key":"10.1016\/j.euroneuro.2024.11.008_bib0018","first-page":"1517","article-title":"Depression is the leading cause of disability around the world","volume":"317","author":"Friedrich","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.euroneuro.2024.11.008_bib0019","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1176\/ps.2009.60.11.1439","article-title":"What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression","volume":"60","author":"Gaynes","year":"2009","journal-title":"Psychiatric Serv."},{"issue":"7","key":"10.1016\/j.euroneuro.2024.11.008_bib0020","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jclp.20279","article-title":"Impact of PTSD comorbidity on one-year outcomes in a depression trial","volume":"62","author":"Green","year":"2006","journal-title":"J. Clin. Psychol."},{"issue":"5","key":"10.1016\/j.euroneuro.2024.11.008_bib0021","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1176\/appi.ajp.162.5.970","article-title":"The impact of comorbid posttraumatic stress disorder on short-term clinical outcome in hospitalized patients with depression","volume":"162","author":"Holtzheimer","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.008_bib0022","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1186\/s12888-020-02935-z","article-title":"Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study","volume":"20","author":"Huang","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.11.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/jts.23013","article-title":"A clinician's guide to the 2023 VA\/DoD clinical practice guideline for management of posttraumatic stress disorder and acute stress disorder","author":"Lang","year":"2024","journal-title":"J. Traumat. Stress"},{"issue":"8","key":"10.1016\/j.euroneuro.2024.11.008_bib0024","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3390\/life13081731","article-title":"Novel pharmacological targets of post-traumatic stress disorders","volume":"13","author":"Marazziti","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.euroneuro.2024.11.008_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2020.104776","article-title":"The roles of comorbidity and trauma exposure and its timing in shaping HPA axis patterns in depression","volume":"120","author":"Mayer","year":"2020","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"10.1016\/j.euroneuro.2024.11.008_bib0026","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.11.008_bib0027","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jad.2021.07.035","article-title":"The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine","volume":"294","author":"McIntyre","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2024.11.008_bib0028","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jad.2020.05.088","article-title":"The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence","volume":"274","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.euroneuro.2024.11.008_bib0029","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m13038","article-title":"Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment","volume":"81","author":"Mohamed","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2024.11.008_bib0030","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/jts.22333","article-title":"Treatment efficacy for veterans with posttraumatic stress disorder: latent class trajectories of treatment response and their predictors","volume":"31","author":"Murphy","year":"2018","journal-title":"J. Traumat. Stress"},{"key":"10.1016\/j.euroneuro.2024.11.008_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102127","article-title":"Ketamine for the treatment of major depression: a systematic review and meta-analysis","volume":"62","author":"Nikolin","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.euroneuro.2024.11.008_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/842817","article-title":"Ketamine, transcranial magnetic stimulation, and depression specific yoga and mindfulness based cognitive therapy in management of treatment resistant depression: review and some data on efficacy","volume":"2015","author":"Pradhan","year":"2015","journal-title":"Depress. Res. Treatm."},{"issue":"10","key":"10.1016\/j.euroneuro.2024.11.008_bib0033","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1007\/s11606-016-3703-5","article-title":"The primary care PTSD screen for DSM-5 (PC-PTSD-5): development and evaluation within a veteran primary care sample","volume":"31","author":"Prins","year":"2016","journal-title":"J. Gener. Internal Med."},{"key":"10.1016\/j.euroneuro.2024.11.008_bib0034","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231154125","article-title":"The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence","volume":"13","author":"Ragnhildstveit","year":"2023","journal-title":"Therapeut. Adv. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.euroneuro.2024.11.008_bib0035","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biolog. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.008_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157340010790596571","article-title":"Expectancy and the treatment of depression: a review of experimental methodology and effects on patient outcome","volume":"6","author":"Rutherford","year":"2010","journal-title":"Curr. Psychiatry Rev."},{"issue":"4","key":"10.1016\/j.euroneuro.2024.11.008_bib0037","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2024.11.008_bib0038","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cct.2014.11.017","article-title":"Design of VA cooperative study #591: CERV-PTSD, comparative effectiveness research in veterans with PTSD","volume":"41","author":"Schnurr","year":"2015","journal-title":"Contemp. Clin. Trial."},{"issue":"11","key":"10.1016\/j.euroneuro.2024.11.008_bib0039","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S2215-0366(22)00317-0","article-title":"Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability","volume":"9","author":"Smith-Apeldoorn","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2024.11.008_bib0040","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.beth.2012.04.003","article-title":"Trajectories of response to treatment for posttraumatic stress disorder","volume":"43","author":"Stein","year":"2012","journal-title":"Behav Ther."},{"issue":"1","key":"10.1016\/j.euroneuro.2024.11.008_bib0041","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/WNF.0000000000000190","article-title":"Quality of life and functioning in comorbid posttraumatic stress disorder and major depressive disorder after treatment with citalopram monotherapy","volume":"40","author":"Steiner","year":"2017","journal-title":"Clin. Neuropharmacol."},{"issue":"Suppl 13","key":"10.1016\/j.euroneuro.2024.11.008_bib0042","first-page":"23","article-title":"When at first you don't succeed: sequential strategies for antidepressant nonresponders","volume":"58","author":"Thase","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2024.11.008_bib0043","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/17512433.2017.1260001","article-title":"Novel pharmacological treatment strategies for posttraumatic stress disorder","volume":"10","author":"Thomas","year":"2017","journal-title":"Exp. Rev. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2024.11.008_bib0044","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1370\/afm.983","article-title":"Defining comorbidity: implications for understanding health and health services","volume":"7","author":"Valderas","year":"2009","journal-title":"Annal. Fam. Med."},{"issue":"06","key":"10.1016\/j.euroneuro.2024.11.008_bib0045","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.4088\/JCP.12r08225","article-title":"Meta-analysis of the efficacy of treatments for posttraumatic stress disorder","volume":"74","author":"Watts","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.euroneuro.2024.11.008_bib0046","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/jclp.23405","article-title":"Diagnostic accuracy of the Primary Care PTSD Screen for DSM-5 (PC-PTSD-5) within a civilian primary care sample","volume":"78","author":"Williamson","year":"2022","journal-title":"J. Clin. Psychol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24007673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X24007673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:05:50Z","timestamp":1738040750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X24007673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":46,"alternative-id":["S0924977X24007673"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.11.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2024.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}